NeuroGen Pharma Limited has recently filed for a listing on the Main Board of the Hong Kong Stock Exchange, with J.P. Morgan, CITIC Securities, and HSBC acting as joint sponsors. Unlike many unprofitable 18A biotech firms, NeuroGen Pharma holds several mature, approved products and reported over RMB 1 billion in revenue and a net profit of RMB 154 million in 2025, demonstrating stable profitability. However, beneath this impressive financial performance lie significant concerns: the company's current product portfolio and pipeline are largely derived from external acquisitions, leaving its in-house research and development foundation relatively weak. The long-term innovation capacity of NeuroGen Pharma remains to be seen. In this IPO, the "substance" of the company's own R&D capabilities will likely be a key focus for the market.
Revenue Largely Relies on Three Proprietary Drugs
According to the prospectus, NeuroGen Pharma was jointly established in June 2024 by CBC Group and Mubadala, each holding a 47.62% stake. In November of the same year, just over five months after its founding and before any actual operations, NeuroGen Pharma completed the acquisition of UCB's neurology and allergy business in China, which had been operating for nearly three decades, for approximately USD 680 million through its wholly-owned subsidiary, NeuroGen Hong Kong. This deal brought mature products like Keppra, Vimpat, and Zyrtec, along with the Zhuhai manufacturing facility, into the fold. UCB Zhuhai was subsequently renamed NeuroGen Zhuhai and became a wholly-owned subsidiary of the group.
Financially, the core operating entity, NeuroGen Zhuhai, recorded revenue of RMB 936 million, RMB 935 million, and RMB 1.152 billion for the years 2023, 2024, and 2025, respectively. Gross profit increased from RMB 424 million to RMB 551 million, while net profit for the same periods was RMB 60.36 million, RMB 30.96 million, and RMB 154 million, showing significant profit volatility. The gross margin steadily improved from 45.3% to 47.9%. At the same time, high debt levels and cost pressures are prominent. To fund the acquisition, NeuroGen Pharma secured a RMB 2 billion syndicated loan from Ping An Bank, pledging the equity of its core subsidiaries, including NeuroGen Zhuhai, NeuroGen Shanghai Trading, and NeuroGen Hong Kong. As of the end of 2025, total interest-bearing borrowings stood at RMB 1.994 billion, with annual interest expenses of RMB 123 million, accounting for over 80% of the group's net profit. Furthermore, while the goodwill of RMB 983 million on the books has not yet been impaired, any impairment event would directly erode profits. As of the same date, the group had cash and cash equivalents of RMB 729 million and operating cash flow of RMB 340 million, but inventory turnover days were as high as 148.7 days, indicating significant working capital tied up. In terms of customer concentration, the top five customers accounted for 80.3%, 79.9%, and 86.6% of revenue from 2023 to 2025, with the single largest customer representing 26.2%, 33.3%, and 32.8% of revenue, respectively. This highlights that the loss of a single customer or order fluctuations could have a direct and significant impact on performance.
On the commercialization front, the company has built an extensive channel network covering 18,000 hospitals, 11,000 medical professionals, and 100,000 pharmacies, supported by a 384-person sales team, making it one of the largest neurology-focused sales forces in China. The Zhuhai base has production capacity for tablets, capsules, and oral solutions, with the annual capacity for Keppra tablets reaching 190 million units, operating at 89.2% capacity in 2025. NeuroGen Pharma is also advancing capacity expansion. In August 2025, it signed a memorandum of cooperation with the Zhuhai High-tech Zone to invest no less than RMB 100 million in building a new plant, primarily to localize the production of Zyrtec drops and a first-in-class analgesic tablet. The project is expected to generate an annual output value of nearly RMB 1 billion upon reaching full production capacity and commenced construction on June 8, 2026.
Product Portfolio and Pipeline
The company currently markets six products, including well-known proprietary drugs such as Keppra, Vimpat, Zyrtec, and the recently approved Ajovy. It also has several pipeline candidates, including NG1706, NG1806, and NG1807, targeting epilepsy, Parkinson's disease, and allergic rhinitis. However, an analysis of the company's revenue structure reveals high concentration. In 2025, out of the total drug sales revenue of RMB 1.319 billion, Keppra contributed RMB 949 million (71.9%), Vimpat contributed RMB 218 million (16.5%), and Zyrtec contributed RMB 131 million (9.9%), collectively accounting for 98.3% of total drug sales. Revenue from other products was negligible. Keppra, a second-generation broad-spectrum anti-epileptic drug with a good safety profile, was approved in China in 2006. However, with generic versions now available from several domestic companies, its future growth potential is limited. Vimpat is a third-generation anti-epileptic product with a differentiated mechanism of action, demonstrating clear efficacy and good tolerability in focal seizures. Zyrtec is a widely recognized second-generation antihistamine available in both tablet and drop formulations, covering needs in pediatrics, ENT, dermatology, and immunology. The company acknowledges that until new products are successfully commercialized, its revenue will remain heavily dependent on a few products like Keppra in the short term, making the risk of a single-product portfolio a significant concern.
Entering the Multi-Billion Yuan Migraine Market, but Long-Term R&D Capacity Remains in Question
While NeuroGen Pharma has introduced several mature products, it has also laid out a few innovative pipeline assets in an attempt to build a second growth curve before the growth of its established products slows. Beyond the three mainstays, Keppra, Vimpat, and Zyrtec, the company has also introduced the migraine proprietary drug Ajovy and pipeline assets like NG1706 (an oral dual-mechanism non-opioid pain management drug), NG1806 (a long-acting dual-mechanism non-opioid post-surgical pain management drug), and NG1807 (an innovative orodispersible film formulation for schizophrenia). Ajovy (fremanezumab injection) is particularly noteworthy, potentially becoming a new revenue pillar by helping the company tap into China's multi-billion yuan migraine prevention market. Migraine is the second leading neurological cause of disability globally, affecting approximately 1.04 billion people worldwide. The global market size was USD 9.6 billion in 2022 and is projected to grow to USD 17.5 billion by 2027, a compound annual growth rate of 9.4%. Ajovy received BLA approval from the National Medical Products Administration (NMPA) in June 2026, and the company plans to submit an age extension application for adolescent patients in the second half of 2026. This drug is the first and only CGRP antagonist approved by the FDA for the prevention of migraine in both children and adults. It was launched in the US and Europe in 2018 and 2019, respectively, and has a proven commercial track record. However, Ajovy faces competition as three other similar CGRP-targeting drugs from Pfizer (rimegepant), Eli Lilly (galcanezumab), and Amgen/Novartis (erenumab) have already been approved in China. As the fourth imported CGRP-targeted therapy, Ajovy's first-mover advantage is not significant.
Regarding other assets, Neupro is the first transdermal dopamine agonist patch for treating Parkinson's disease in China. Its once-daily, non-oral delivery helps reduce the "end-of-dose wearing-off" phenomenon commonly seen with oral therapies, potentially reshaping treatment paradigms. NG1706 is an innovative oral dual-mechanism non-opioid analgesic that shows potential as a differentiated non-opioid alternative in post-surgical pain management. NG1806 is a long-acting dual-mechanism non-opioid pain management drug designed to provide 72 hours of pain relief and is expected to become the first such product in China. Its clinical value includes reducing opioid exposure, shortening hospital stays, and improving post-operative recovery. A Phase III trial is expected to start in 2026. NG1807 is a brexpiprazole orodispersible film for which an NDA has been submitted and is under review. Upon approval, the company plans to expand its use to agitation associated with Alzheimer's disease (an indication already approved in the US).
Despite these efforts, NeuroGen Pharma's own R&D capabilities are notably weak. In 2025, the company's total R&D expenditure was a mere RMB 5.07 million, representing just 0.4% of its revenue. This spending was heavily skewed towards outsourcing services (84.4%) and employee costs (14.9%), underscoring a severe lack of internal R&D intensity. Whether the company can successfully advance its pipeline candidates remains a significant question. More critically, the cost pressures of the business development (BD) and in-licensing model will become more apparent over time. Under licensing agreements, the company is obligated to pay upfront fees, development milestones, sales milestones, and tiered royalties. For example, the sales royalty for Ajovy is typically in the range of 10% to 20% of net sales, which will continuously erode product margins and further squeeze profitability.
Overall, while NeuroGen Pharma has leveraged capital deployment to build a mature commercial product pipeline and deliver a strong financial report, as a biotech innovator, the depth of its pipeline and its own R&D capabilities are the true foundations of its competitive moat. If the company fails to genuinely strengthen its R&D efforts, its path forward after a successful listing is likely to be fraught with challenges and uncertainty.
Comments